Science and Research

Glycans and glycan-specific IgE in clinical and molecular allergology: Sensitization, diagnostics, and clinical symptoms

Glycan-specific IgE antibodies cross-react with highly similar or even identical carbohydrate structures on a variety of different natural allergens, the so-called cross-reactive carbohydrate determinants (CCDs). In clinical practice CCDs often interfere with the specificity of in vitro allergy diagnostics, thus impairing allergy therapy decisions for individual patients. Strikingly, these IgE antibodies directed against CCDs often do not cause clinically relevant allergy symptoms. On the other hand, the IgE-binding glycan allergen galactose-alpha-(1,3)-galactose (alpha-Gal) is associated with IgE-mediated delayed anaphylaxis in meat allergy. The reason for this discrepancy is not known. The discovery of alpha-Gal stimulated new discussions and investigations regarding the relevance of anti-glycan IgE for allergic diseases. In this review the effect of glycans and glycan-specific IgE on sensitization to allergens and allergy diagnosis is described. Because parasite infections elicit a similar immunologic environment as allergic diseases, the association of glycan-specific antibodies against parasite glycoproteins with glycan structures on allergens is discussed.

  • Homann, A.
  • Schramm, G.
  • Jappe, U.

Keywords

  • Allergens/*immunology
  • Cross Reactions
  • Humans
  • Hypersensitivity/immunology
  • Immune Tolerance
  • Immunoglobulin E/*immunology
  • Polysaccharides/*immunology
  • Th2 Cells/immunology
  • Cross-reactive carbohydrate determinants
  • Schistosoma species
  • anaphylaxis
  • anti-glycan IgE
  • clinical allergology
  • galactose-alpha-(1,3)-galactose
  • molecular allergology
  • parasite immunomodulation
Publication details
DOI: 10.1016/j.jaci.2017.04.019
Journal: The Journal of allergy and clinical immunology
Pages: 356-368 
Number: 2
Work Type: Review
Location: ARCN
Disease Area: AA
Partner / Member: FZB
Access-Number: 28479330
See publication on PubMed

DZL Engagements

chevron-down